Global Drugs for Vulvovaginal Candidiasis Market

Drugs for Vulvovaginal Candidiasis Comprehensive Study by Type (Miconazole, Clotrimazole, Fluconazole, Econazole, Other), Application (Clotrimazole,, Miconazole,, Terconazole,, Tioconazole,), Formulation (Cream, Pessary, Other), End User (Hospital & Clinic, Pharmacy) Players and Region - Global Market Outlook to 2028

Drugs for Vulvovaginal Candidiasis Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Drugs for Vulvovaginal Candidiasis is the medicine that is used to cure vulvovaginal candidiasis. Vulvovaginal Candidiasis is also called as vaginal thrush. There are various types of Drugs for Vulvovaginal Candidiasis including miconazole, clotrimazole, fluconazole, econazole and other. This drug is formulated in different types including cream, pessary and other. Increase in number of patients affected by candidiasis infection and high adoption due to innovative drugs will help to boost global drugs for vulvovaginal candidiasis market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer (Germany), Perrigo (Ireland), J & J (United States), Pfizer (United States), Bristol-Myers Squibb (United States), Effik (France), Teva (Israel), Sanofi (France), Cisen Pharmaceutical (China) and STELLAR PHARMA LTD (United Kingdom)


This growth is primarily driven by Increase in Number of Patients Affected By Candidiasis Infection and High Adoption due to Innovative Drugs for Vulvovaginal Candidiasis.

Globally, a noticeable market trend is evident Increasing Consumer Inclination towards Maintaining Aesthetic Appearance Major Players, such as Bayer (Germany), Perrigo (Ireland), J & J (United States), Pfizer (United States), Bristol-Myers Squibb (United States), Effik (France), Teva (Israel), Sanofi (France), Cisen Pharmaceutical (China) and STELLAR PHARMA LTD (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market is fragmented by key vendors who are focusing on production technologies, improving efficiency. Growth opportunities can be captured by tracking the ongoing process improvement and financial flexibility to invest in optimal strategies.

Key Developments in the Market:
In October 2022 Astellas Pharma Inc. and Panthera Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
In July 2021, Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced the U.S.

Influencing Trend:
Increasing Consumer Inclination towards Maintaining Aesthetic Appearance and Rising Hygiene Awareness in Developing Countries

Market Growth Drivers:
Increase in Number of Patients Affected By Candidiasis Infection and High Adoption due to Innovative Drugs for Vulvovaginal Candidiasis

Challenges:
Competition from Herbal Medicines and Alternative Therapies

Restraints:
Narrow Pipeline Molecules and Less R&D Activity

Opportunities:
Growing Awareness for Candidiasis Infection in Developing Markets

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Drugs for Vulvovaginal Candidiasis Market
- Analysis about New Entrants in Drugs for Vulvovaginal Candidiasis Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Drugs for Vulvovaginal Candidiasis Study Sheds Light on
— The Drugs for Vulvovaginal Candidiasis Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Drugs for Vulvovaginal Candidiasis industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Drugs for Vulvovaginal Candidiasis industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Miconazole
  • Clotrimazole
  • Fluconazole
  • Econazole
  • Other
By Application
  • clotrimazole,
  • miconazole,
  • terconazole,
  • tioconazole,
By Formulation
  • Cream
  • Pessary
  • Other

By End User
  • Hospital & Clinic
  • Pharmacy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Number of Patients Affected By Candidiasis Infection
      • 3.2.2. High Adoption due to Innovative Drugs for Vulvovaginal Candidiasis
    • 3.3. Market Challenges
      • 3.3.1. Competition from Herbal Medicines and Alternative Therapies
    • 3.4. Market Trends
      • 3.4.1. Increasing Consumer Inclination towards Maintaining Aesthetic Appearance
      • 3.4.2. Rising Hygiene Awareness in Developing Countries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drugs for Vulvovaginal Candidiasis, by Type, Application, Formulation, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drugs for Vulvovaginal Candidiasis (Value)
      • 5.2.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Value)
        • 5.2.1.1. Miconazole
        • 5.2.1.2. Clotrimazole
        • 5.2.1.3. Fluconazole
        • 5.2.1.4. Econazole
        • 5.2.1.5. Other
      • 5.2.2. Global Drugs for Vulvovaginal Candidiasis by: Application (Value)
        • 5.2.2.1. Clotrimazole,
        • 5.2.2.2. Miconazole,
        • 5.2.2.3. Terconazole,
        • 5.2.2.4. Tioconazole,
      • 5.2.3. Global Drugs for Vulvovaginal Candidiasis by: Formulation (Value)
        • 5.2.3.1. Cream
        • 5.2.3.2. Pessary
        • 5.2.3.3. Other
      • 5.2.4. Global Drugs for Vulvovaginal Candidiasis by: End User (Value)
        • 5.2.4.1. Hospital & Clinic
        • 5.2.4.2. Pharmacy
      • 5.2.5. Global Drugs for Vulvovaginal Candidiasis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Drugs for Vulvovaginal Candidiasis (Volume)
      • 5.3.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Volume)
        • 5.3.1.1. Miconazole
        • 5.3.1.2. Clotrimazole
        • 5.3.1.3. Fluconazole
        • 5.3.1.4. Econazole
        • 5.3.1.5. Other
      • 5.3.2. Global Drugs for Vulvovaginal Candidiasis by: Application (Volume)
        • 5.3.2.1. Clotrimazole,
        • 5.3.2.2. Miconazole,
        • 5.3.2.3. Terconazole,
        • 5.3.2.4. Tioconazole,
      • 5.3.3. Global Drugs for Vulvovaginal Candidiasis by: Formulation (Volume)
        • 5.3.3.1. Cream
        • 5.3.3.2. Pessary
        • 5.3.3.3. Other
      • 5.3.4. Global Drugs for Vulvovaginal Candidiasis by: End User (Volume)
        • 5.3.4.1. Hospital & Clinic
        • 5.3.4.2. Pharmacy
      • 5.3.5. Global Drugs for Vulvovaginal Candidiasis Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Drugs for Vulvovaginal Candidiasis (Price)
      • 5.4.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Price)
  • 6. Drugs for Vulvovaginal Candidiasis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Perrigo (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. J & J (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Effik (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cisen Pharmaceutical (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. STELLAR PHARMA LTD (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drugs for Vulvovaginal Candidiasis Sale, by Type, Application, Formulation, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drugs for Vulvovaginal Candidiasis (Value)
      • 7.2.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Value)
        • 7.2.1.1. Miconazole
        • 7.2.1.2. Clotrimazole
        • 7.2.1.3. Fluconazole
        • 7.2.1.4. Econazole
        • 7.2.1.5. Other
      • 7.2.2. Global Drugs for Vulvovaginal Candidiasis by: Application (Value)
        • 7.2.2.1. Clotrimazole,
        • 7.2.2.2. Miconazole,
        • 7.2.2.3. Terconazole,
        • 7.2.2.4. Tioconazole,
      • 7.2.3. Global Drugs for Vulvovaginal Candidiasis by: Formulation (Value)
        • 7.2.3.1. Cream
        • 7.2.3.2. Pessary
        • 7.2.3.3. Other
      • 7.2.4. Global Drugs for Vulvovaginal Candidiasis by: End User (Value)
        • 7.2.4.1. Hospital & Clinic
        • 7.2.4.2. Pharmacy
      • 7.2.5. Global Drugs for Vulvovaginal Candidiasis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Drugs for Vulvovaginal Candidiasis (Volume)
      • 7.3.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Volume)
        • 7.3.1.1. Miconazole
        • 7.3.1.2. Clotrimazole
        • 7.3.1.3. Fluconazole
        • 7.3.1.4. Econazole
        • 7.3.1.5. Other
      • 7.3.2. Global Drugs for Vulvovaginal Candidiasis by: Application (Volume)
        • 7.3.2.1. Clotrimazole,
        • 7.3.2.2. Miconazole,
        • 7.3.2.3. Terconazole,
        • 7.3.2.4. Tioconazole,
      • 7.3.3. Global Drugs for Vulvovaginal Candidiasis by: Formulation (Volume)
        • 7.3.3.1. Cream
        • 7.3.3.2. Pessary
        • 7.3.3.3. Other
      • 7.3.4. Global Drugs for Vulvovaginal Candidiasis by: End User (Volume)
        • 7.3.4.1. Hospital & Clinic
        • 7.3.4.2. Pharmacy
      • 7.3.5. Global Drugs for Vulvovaginal Candidiasis Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Drugs for Vulvovaginal Candidiasis (Price)
      • 7.4.1. Global Drugs for Vulvovaginal Candidiasis by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drugs for Vulvovaginal Candidiasis: by Type(USD Million)
  • Table 2. Drugs for Vulvovaginal Candidiasis Miconazole , by Region USD Million (2017-2022)
  • Table 3. Drugs for Vulvovaginal Candidiasis Clotrimazole , by Region USD Million (2017-2022)
  • Table 4. Drugs for Vulvovaginal Candidiasis Fluconazole , by Region USD Million (2017-2022)
  • Table 5. Drugs for Vulvovaginal Candidiasis Econazole , by Region USD Million (2017-2022)
  • Table 6. Drugs for Vulvovaginal Candidiasis Other , by Region USD Million (2017-2022)
  • Table 7. Drugs for Vulvovaginal Candidiasis: by Application(USD Million)
  • Table 8. Drugs for Vulvovaginal Candidiasis Clotrimazole, , by Region USD Million (2017-2022)
  • Table 9. Drugs for Vulvovaginal Candidiasis Miconazole, , by Region USD Million (2017-2022)
  • Table 10. Drugs for Vulvovaginal Candidiasis Terconazole, , by Region USD Million (2017-2022)
  • Table 11. Drugs for Vulvovaginal Candidiasis Tioconazole, , by Region USD Million (2017-2022)
  • Table 12. Drugs for Vulvovaginal Candidiasis: by Formulation(USD Million)
  • Table 13. Drugs for Vulvovaginal Candidiasis Cream , by Region USD Million (2017-2022)
  • Table 14. Drugs for Vulvovaginal Candidiasis Pessary , by Region USD Million (2017-2022)
  • Table 15. Drugs for Vulvovaginal Candidiasis Other , by Region USD Million (2017-2022)
  • Table 16. Drugs for Vulvovaginal Candidiasis: by End User(USD Million)
  • Table 17. Drugs for Vulvovaginal Candidiasis Hospital & Clinic , by Region USD Million (2017-2022)
  • Table 18. Drugs for Vulvovaginal Candidiasis Pharmacy , by Region USD Million (2017-2022)
  • Table 19. South America Drugs for Vulvovaginal Candidiasis, by Country USD Million (2017-2022)
  • Table 20. South America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 21. South America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 22. South America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 23. South America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 24. Brazil Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 25. Brazil Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 26. Brazil Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 27. Brazil Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 28. Argentina Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 29. Argentina Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 30. Argentina Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 31. Argentina Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 32. Rest of South America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 33. Rest of South America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 34. Rest of South America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 35. Rest of South America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 36. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 40. Asia Pacific Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 41. China Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 42. China Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 43. China Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 44. China Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 45. Japan Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 46. Japan Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 47. Japan Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 48. Japan Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 49. India Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 50. India Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 51. India Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 52. India Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 53. South Korea Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 54. South Korea Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 55. South Korea Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 56. South Korea Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 57. Taiwan Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 58. Taiwan Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 59. Taiwan Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 60. Taiwan Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 61. Australia Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 62. Australia Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 63. Australia Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 64. Australia Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 69. Europe Drugs for Vulvovaginal Candidiasis, by Country USD Million (2017-2022)
  • Table 70. Europe Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 71. Europe Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 72. Europe Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 73. Europe Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 74. Germany Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 75. Germany Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 76. Germany Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 77. Germany Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 78. France Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 79. France Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 80. France Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 81. France Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 82. Italy Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 83. Italy Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 84. Italy Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 85. Italy Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 86. United Kingdom Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 87. United Kingdom Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 88. United Kingdom Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 89. United Kingdom Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 90. Netherlands Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 91. Netherlands Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 92. Netherlands Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 93. Netherlands Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 94. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 95. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 96. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 97. Rest of Europe Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 98. MEA Drugs for Vulvovaginal Candidiasis, by Country USD Million (2017-2022)
  • Table 99. MEA Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 100. MEA Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 101. MEA Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 102. MEA Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 103. Middle East Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 104. Middle East Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 105. Middle East Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 106. Middle East Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 107. Africa Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 108. Africa Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 109. Africa Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 110. Africa Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 111. North America Drugs for Vulvovaginal Candidiasis, by Country USD Million (2017-2022)
  • Table 112. North America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 113. North America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 114. North America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 115. North America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 116. United States Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 117. United States Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 118. United States Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 119. United States Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 120. Canada Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 121. Canada Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 122. Canada Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 123. Canada Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 124. Mexico Drugs for Vulvovaginal Candidiasis, by Type USD Million (2017-2022)
  • Table 125. Mexico Drugs for Vulvovaginal Candidiasis, by Application USD Million (2017-2022)
  • Table 126. Mexico Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2017-2022)
  • Table 127. Mexico Drugs for Vulvovaginal Candidiasis, by End User USD Million (2017-2022)
  • Table 128. Drugs for Vulvovaginal Candidiasis Sales: by Type(K Units)
  • Table 129. Drugs for Vulvovaginal Candidiasis Sales Miconazole , by Region K Units (2017-2022)
  • Table 130. Drugs for Vulvovaginal Candidiasis Sales Clotrimazole , by Region K Units (2017-2022)
  • Table 131. Drugs for Vulvovaginal Candidiasis Sales Fluconazole , by Region K Units (2017-2022)
  • Table 132. Drugs for Vulvovaginal Candidiasis Sales Econazole , by Region K Units (2017-2022)
  • Table 133. Drugs for Vulvovaginal Candidiasis Sales Other , by Region K Units (2017-2022)
  • Table 134. Drugs for Vulvovaginal Candidiasis Sales: by Application(K Units)
  • Table 135. Drugs for Vulvovaginal Candidiasis Sales Clotrimazole, , by Region K Units (2017-2022)
  • Table 136. Drugs for Vulvovaginal Candidiasis Sales Miconazole, , by Region K Units (2017-2022)
  • Table 137. Drugs for Vulvovaginal Candidiasis Sales Terconazole, , by Region K Units (2017-2022)
  • Table 138. Drugs for Vulvovaginal Candidiasis Sales Tioconazole, , by Region K Units (2017-2022)
  • Table 139. Drugs for Vulvovaginal Candidiasis Sales: by Formulation(K Units)
  • Table 140. Drugs for Vulvovaginal Candidiasis Sales Cream , by Region K Units (2017-2022)
  • Table 141. Drugs for Vulvovaginal Candidiasis Sales Pessary , by Region K Units (2017-2022)
  • Table 142. Drugs for Vulvovaginal Candidiasis Sales Other , by Region K Units (2017-2022)
  • Table 143. Drugs for Vulvovaginal Candidiasis Sales: by End User(K Units)
  • Table 144. Drugs for Vulvovaginal Candidiasis Sales Hospital & Clinic , by Region K Units (2017-2022)
  • Table 145. Drugs for Vulvovaginal Candidiasis Sales Pharmacy , by Region K Units (2017-2022)
  • Table 146. South America Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2017-2022)
  • Table 147. South America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 148. South America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 149. South America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 150. South America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 151. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 152. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 153. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 154. Brazil Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 155. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 156. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 157. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 158. Argentina Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 159. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 160. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 161. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 162. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 163. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2017-2022)
  • Table 164. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 165. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 166. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 167. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 168. China Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 169. China Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 170. China Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 171. China Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 172. Japan Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 173. Japan Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 174. Japan Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 175. Japan Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 176. India Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 177. India Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 178. India Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 179. India Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 180. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 181. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 182. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 183. South Korea Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 184. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 185. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 186. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 187. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 188. Australia Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 189. Australia Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 190. Australia Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 191. Australia Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 192. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 193. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 194. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 195. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 196. Europe Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2017-2022)
  • Table 197. Europe Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 198. Europe Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 199. Europe Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 200. Europe Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 201. Germany Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 202. Germany Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 203. Germany Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 204. Germany Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 205. France Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 206. France Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 207. France Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 208. France Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 209. Italy Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 210. Italy Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 211. Italy Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 212. Italy Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 213. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 214. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 215. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 216. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 217. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 218. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 219. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 220. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 221. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 222. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 223. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 224. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 225. MEA Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2017-2022)
  • Table 226. MEA Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 227. MEA Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 228. MEA Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 229. MEA Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 230. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 231. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 232. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 233. Middle East Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 234. Africa Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 235. Africa Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 236. Africa Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 237. Africa Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 238. North America Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2017-2022)
  • Table 239. North America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 240. North America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 241. North America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 242. North America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 243. United States Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 244. United States Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 245. United States Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 246. United States Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 247. Canada Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 248. Canada Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 249. Canada Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 250. Canada Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 251. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2017-2022)
  • Table 252. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2017-2022)
  • Table 253. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2017-2022)
  • Table 254. Mexico Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2017-2022)
  • Table 255. Drugs for Vulvovaginal Candidiasis: by Type(USD/Units)
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Drugs for Vulvovaginal Candidiasis: by Type(USD Million)
  • Table 267. Drugs for Vulvovaginal Candidiasis Miconazole , by Region USD Million (2023-2028)
  • Table 268. Drugs for Vulvovaginal Candidiasis Clotrimazole , by Region USD Million (2023-2028)
  • Table 269. Drugs for Vulvovaginal Candidiasis Fluconazole , by Region USD Million (2023-2028)
  • Table 270. Drugs for Vulvovaginal Candidiasis Econazole , by Region USD Million (2023-2028)
  • Table 271. Drugs for Vulvovaginal Candidiasis Other , by Region USD Million (2023-2028)
  • Table 272. Drugs for Vulvovaginal Candidiasis: by Application(USD Million)
  • Table 273. Drugs for Vulvovaginal Candidiasis Clotrimazole, , by Region USD Million (2023-2028)
  • Table 274. Drugs for Vulvovaginal Candidiasis Miconazole, , by Region USD Million (2023-2028)
  • Table 275. Drugs for Vulvovaginal Candidiasis Terconazole, , by Region USD Million (2023-2028)
  • Table 276. Drugs for Vulvovaginal Candidiasis Tioconazole, , by Region USD Million (2023-2028)
  • Table 277. Drugs for Vulvovaginal Candidiasis: by Formulation(USD Million)
  • Table 278. Drugs for Vulvovaginal Candidiasis Cream , by Region USD Million (2023-2028)
  • Table 279. Drugs for Vulvovaginal Candidiasis Pessary , by Region USD Million (2023-2028)
  • Table 280. Drugs for Vulvovaginal Candidiasis Other , by Region USD Million (2023-2028)
  • Table 281. Drugs for Vulvovaginal Candidiasis: by End User(USD Million)
  • Table 282. Drugs for Vulvovaginal Candidiasis Hospital & Clinic , by Region USD Million (2023-2028)
  • Table 283. Drugs for Vulvovaginal Candidiasis Pharmacy , by Region USD Million (2023-2028)
  • Table 284. South America Drugs for Vulvovaginal Candidiasis, by Country USD Million (2023-2028)
  • Table 285. South America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 286. South America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 287. South America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 288. South America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 289. Brazil Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 290. Brazil Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 291. Brazil Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 292. Brazil Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 293. Argentina Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 294. Argentina Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 295. Argentina Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 296. Argentina Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 297. Rest of South America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 298. Rest of South America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 299. Rest of South America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 300. Rest of South America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 301. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Country USD Million (2023-2028)
  • Table 302. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 303. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 304. Asia Pacific Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 305. Asia Pacific Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 306. China Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 307. China Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 308. China Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 309. China Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 310. Japan Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 311. Japan Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 312. Japan Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 313. Japan Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 314. India Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 315. India Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 316. India Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 317. India Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 318. South Korea Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 319. South Korea Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 320. South Korea Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 321. South Korea Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 322. Taiwan Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 323. Taiwan Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 324. Taiwan Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 325. Taiwan Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 326. Australia Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 327. Australia Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 328. Australia Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 329. Australia Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 330. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 331. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 332. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 333. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 334. Europe Drugs for Vulvovaginal Candidiasis, by Country USD Million (2023-2028)
  • Table 335. Europe Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 336. Europe Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 337. Europe Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 338. Europe Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 339. Germany Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 340. Germany Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 341. Germany Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 342. Germany Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 343. France Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 344. France Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 345. France Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 346. France Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 347. Italy Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 348. Italy Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 349. Italy Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 350. Italy Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 351. United Kingdom Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 352. United Kingdom Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 353. United Kingdom Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 354. United Kingdom Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 355. Netherlands Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 356. Netherlands Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 357. Netherlands Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 358. Netherlands Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 359. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 360. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 361. Rest of Europe Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 362. Rest of Europe Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 363. MEA Drugs for Vulvovaginal Candidiasis, by Country USD Million (2023-2028)
  • Table 364. MEA Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 365. MEA Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 366. MEA Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 367. MEA Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 368. Middle East Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 369. Middle East Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 370. Middle East Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 371. Middle East Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 372. Africa Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 373. Africa Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 374. Africa Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 375. Africa Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 376. North America Drugs for Vulvovaginal Candidiasis, by Country USD Million (2023-2028)
  • Table 377. North America Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 378. North America Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 379. North America Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 380. North America Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 381. United States Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 382. United States Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 383. United States Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 384. United States Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 385. Canada Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 386. Canada Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 387. Canada Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 388. Canada Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 389. Mexico Drugs for Vulvovaginal Candidiasis, by Type USD Million (2023-2028)
  • Table 390. Mexico Drugs for Vulvovaginal Candidiasis, by Application USD Million (2023-2028)
  • Table 391. Mexico Drugs for Vulvovaginal Candidiasis, by Formulation USD Million (2023-2028)
  • Table 392. Mexico Drugs for Vulvovaginal Candidiasis, by End User USD Million (2023-2028)
  • Table 393. Drugs for Vulvovaginal Candidiasis Sales: by Type(K Units)
  • Table 394. Drugs for Vulvovaginal Candidiasis Sales Miconazole , by Region K Units (2023-2028)
  • Table 395. Drugs for Vulvovaginal Candidiasis Sales Clotrimazole , by Region K Units (2023-2028)
  • Table 396. Drugs for Vulvovaginal Candidiasis Sales Fluconazole , by Region K Units (2023-2028)
  • Table 397. Drugs for Vulvovaginal Candidiasis Sales Econazole , by Region K Units (2023-2028)
  • Table 398. Drugs for Vulvovaginal Candidiasis Sales Other , by Region K Units (2023-2028)
  • Table 399. Drugs for Vulvovaginal Candidiasis Sales: by Application(K Units)
  • Table 400. Drugs for Vulvovaginal Candidiasis Sales Clotrimazole, , by Region K Units (2023-2028)
  • Table 401. Drugs for Vulvovaginal Candidiasis Sales Miconazole, , by Region K Units (2023-2028)
  • Table 402. Drugs for Vulvovaginal Candidiasis Sales Terconazole, , by Region K Units (2023-2028)
  • Table 403. Drugs for Vulvovaginal Candidiasis Sales Tioconazole, , by Region K Units (2023-2028)
  • Table 404. Drugs for Vulvovaginal Candidiasis Sales: by Formulation(K Units)
  • Table 405. Drugs for Vulvovaginal Candidiasis Sales Cream , by Region K Units (2023-2028)
  • Table 406. Drugs for Vulvovaginal Candidiasis Sales Pessary , by Region K Units (2023-2028)
  • Table 407. Drugs for Vulvovaginal Candidiasis Sales Other , by Region K Units (2023-2028)
  • Table 408. Drugs for Vulvovaginal Candidiasis Sales: by End User(K Units)
  • Table 409. Drugs for Vulvovaginal Candidiasis Sales Hospital & Clinic , by Region K Units (2023-2028)
  • Table 410. Drugs for Vulvovaginal Candidiasis Sales Pharmacy , by Region K Units (2023-2028)
  • Table 411. South America Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2023-2028)
  • Table 412. South America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 413. South America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 414. South America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 415. South America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 416. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 417. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 418. Brazil Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 419. Brazil Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 420. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 421. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 422. Argentina Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 423. Argentina Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 424. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 425. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 426. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 427. Rest of South America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 428. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2023-2028)
  • Table 429. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 430. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 431. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 432. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 433. China Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 434. China Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 435. China Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 436. China Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 437. Japan Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 438. Japan Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 439. Japan Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 440. Japan Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 441. India Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 442. India Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 443. India Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 444. India Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 445. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 446. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 447. South Korea Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 448. South Korea Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 449. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 450. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 451. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 452. Taiwan Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 453. Australia Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 454. Australia Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 455. Australia Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 456. Australia Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 457. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 458. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 459. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 460. Rest of Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 461. Europe Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2023-2028)
  • Table 462. Europe Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 463. Europe Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 464. Europe Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 465. Europe Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 466. Germany Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 467. Germany Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 468. Germany Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 469. Germany Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 470. France Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 471. France Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 472. France Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 473. France Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 474. Italy Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 475. Italy Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 476. Italy Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 477. Italy Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 478. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 479. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 480. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 481. United Kingdom Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 482. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 483. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 484. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 485. Netherlands Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 486. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 487. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 488. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 489. Rest of Europe Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 490. MEA Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2023-2028)
  • Table 491. MEA Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 492. MEA Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 493. MEA Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 494. MEA Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 495. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 496. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 497. Middle East Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 498. Middle East Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 499. Africa Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 500. Africa Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 501. Africa Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 502. Africa Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 503. North America Drugs for Vulvovaginal Candidiasis Sales, by Country K Units (2023-2028)
  • Table 504. North America Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 505. North America Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 506. North America Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 507. North America Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 508. United States Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 509. United States Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 510. United States Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 511. United States Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 512. Canada Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 513. Canada Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 514. Canada Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 515. Canada Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 516. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Type K Units (2023-2028)
  • Table 517. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Application K Units (2023-2028)
  • Table 518. Mexico Drugs for Vulvovaginal Candidiasis Sales, by Formulation K Units (2023-2028)
  • Table 519. Mexico Drugs for Vulvovaginal Candidiasis Sales, by End User K Units (2023-2028)
  • Table 520. Drugs for Vulvovaginal Candidiasis: by Type(USD/Units)
  • Table 521. Research Programs/Design for This Report
  • Table 522. Key Data Information from Secondary Sources
  • Table 523. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drugs for Vulvovaginal Candidiasis: by Type USD Million (2017-2022)
  • Figure 5. Global Drugs for Vulvovaginal Candidiasis: by Application USD Million (2017-2022)
  • Figure 6. Global Drugs for Vulvovaginal Candidiasis: by Formulation USD Million (2017-2022)
  • Figure 7. Global Drugs for Vulvovaginal Candidiasis: by End User USD Million (2017-2022)
  • Figure 8. South America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 9. Asia Pacific Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 10. Europe Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 11. MEA Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 12. North America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 13. Global Drugs for Vulvovaginal Candidiasis: by Type K Units (2017-2022)
  • Figure 14. Global Drugs for Vulvovaginal Candidiasis: by Application K Units (2017-2022)
  • Figure 15. Global Drugs for Vulvovaginal Candidiasis: by Formulation K Units (2017-2022)
  • Figure 16. Global Drugs for Vulvovaginal Candidiasis: by End User K Units (2017-2022)
  • Figure 17. South America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 18. Asia Pacific Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 19. Europe Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 20. MEA Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 21. North America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 22. Global Drugs for Vulvovaginal Candidiasis: by Type USD/Units (2017-2022)
  • Figure 23. Global Drugs for Vulvovaginal Candidiasis share by Players 2022 (%)
  • Figure 24. Global Drugs for Vulvovaginal Candidiasis share by Players (Top 3) 2022(%)
  • Figure 25. Global Drugs for Vulvovaginal Candidiasis share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Bayer (Germany) Revenue: by Geography 2022
  • Figure 29. Perrigo (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Perrigo (Ireland) Revenue: by Geography 2022
  • Figure 31. J & J (United States) Revenue, Net Income and Gross profit
  • Figure 32. J & J (United States) Revenue: by Geography 2022
  • Figure 33. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer (United States) Revenue: by Geography 2022
  • Figure 35. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bristol-Myers Squibb (United States) Revenue: by Geography 2022
  • Figure 37. Effik (France) Revenue, Net Income and Gross profit
  • Figure 38. Effik (France) Revenue: by Geography 2022
  • Figure 39. Teva (Israel) Revenue, Net Income and Gross profit
  • Figure 40. Teva (Israel) Revenue: by Geography 2022
  • Figure 41. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 42. Sanofi (France) Revenue: by Geography 2022
  • Figure 43. Cisen Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 44. Cisen Pharmaceutical (China) Revenue: by Geography 2022
  • Figure 45. STELLAR PHARMA LTD (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 46. STELLAR PHARMA LTD (United Kingdom) Revenue: by Geography 2022
  • Figure 47. Global Drugs for Vulvovaginal Candidiasis: by Type USD Million (2023-2028)
  • Figure 48. Global Drugs for Vulvovaginal Candidiasis: by Application USD Million (2023-2028)
  • Figure 49. Global Drugs for Vulvovaginal Candidiasis: by Formulation USD Million (2023-2028)
  • Figure 50. Global Drugs for Vulvovaginal Candidiasis: by End User USD Million (2023-2028)
  • Figure 51. South America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 52. Asia Pacific Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 53. Europe Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 54. MEA Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 55. North America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 56. Global Drugs for Vulvovaginal Candidiasis: by Type K Units (2023-2028)
  • Figure 57. Global Drugs for Vulvovaginal Candidiasis: by Application K Units (2023-2028)
  • Figure 58. Global Drugs for Vulvovaginal Candidiasis: by Formulation K Units (2023-2028)
  • Figure 59. Global Drugs for Vulvovaginal Candidiasis: by End User K Units (2023-2028)
  • Figure 60. South America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 61. Asia Pacific Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 62. Europe Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 63. MEA Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 64. North America Drugs for Vulvovaginal Candidiasis Share (%), by Country
  • Figure 65. Global Drugs for Vulvovaginal Candidiasis: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Bayer (Germany)
  • Perrigo (Ireland)
  • J & J (United States)
  • Pfizer (United States)
  • Bristol-Myers Squibb (United States)
  • Effik (France)
  • Teva (Israel)
  • Sanofi (France)
  • Cisen Pharmaceutical (China)
  • STELLAR PHARMA LTD (United Kingdom)
Additional players considered in the study are as follows:
Glenmark Pharmaceuticals (India) , Kingyork Group (China) , Ranbaxy (India)
Select User Access Type

Key Highlights of Report


Dec 2023 242 Pages 57 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drugs for Vulvovaginal Candidiasis Market Quantitative research analysis
Global Drugs for Vulvovaginal Candidiasis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Drugs for Vulvovaginal Candidiasis market are Bayer (Germany), Perrigo (Ireland), J & J (United States), Pfizer (United States), Bristol-Myers Squibb (United States), Effik (France), Teva (Israel), Sanofi (France), Cisen Pharmaceutical (China) and STELLAR PHARMA LTD (United Kingdom), to name a few.
is dominating the Drugs for Vulvovaginal Candidiasis Market.
"Competition from Herbal Medicines and Alternative Therapies" is seen as one of the major challenges by many Industry Players of Drugs for Vulvovaginal Candidiasis Market
The Drugs for Vulvovaginal Candidiasis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Drugs for Vulvovaginal Candidiasis market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Drugs for Vulvovaginal Candidiasis Market Report?

Have a Query? Click Here

Other Related Reports

Achondroplasia Treatment Comprehensive Study by Type (RBM-007, TA-46, B-701, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Hemoperfusion Comprehensive Study by Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion), Application (Drug Intoxication, Hepatic Encephalopathy, Others), Hemoperfusion Devices (DiaKart, Bioc...
$ 3750
Etanercept Comprehensive Study by Type (Enbrel, Benepali), Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA), Others), Form Type (Inj...
$ 3650
Radiotherapy Comprehensive Study by Type (External Beam Radiotherapy (IMRT, IGRT, Others), Internal Beam Radiotherapy (LDR, HDR, PDR), Systemic Radiotherapy), Application (Prostate Cancer, Breast Can...
$ 3750
Autism Spectrum Disorder Comprehensive Study by Type (Applied Behavior Analysis, Discrete Trial Teaching, Pivotal Response Treatment), Indication (Insomnia, Epilepsy, Depression, Hyperactivity & Inat...
$ 3450
Blood Serum Comprehensive Study by Type (Bovine (Fetal Bovine, Newborn Calf, Calf, Adult Bovine), Equine, Porcine, Other), Application (Cell Culture Media, Cell Line Saving, Tissue Culture, Diagnosti...
$ 3500